Monthly
Topic...
Coronary
Balloon Angioplasty (PTCA)
What is balloon
angioplasty?
Balloon angioplasty of the coronary artery, or percutaneous
transluminal coronary angioplasty (PTCA), is a relatively new
procedure introduced in the late 1970's. PTCA is a non-surgical
procedure that relieves narrowing and obstruction of the arteries to
the muscle of the heart (coronary arteries). This allows more blood
and oxygen to be delivered to the heart muscle. PTCA is accomplished
with a small balloon catheter inserted into an artery in the groin or
arm, and advanced to the narrowing in the coronary artery. The balloon
is then inflated to enlarge the narrowing in the artery. When
successful, PTCA can relieve chest pain of angina, improve the
prognosis of patients with unstable angina, and minimize or stop a
heart attack without having the patient undergo open heart coronary
artery bypass graft (CABG) surgery.

In addition to the use
of simple balloon angioplasty, the availability of stainless steel
stents, in a wire-mesh design, have expanded the spectrum of patients
suitable for PTCA, as well as enhanced the safety and long-term
results of the procedure. Various "atherectomy" (plaque
removal) devices are also available as adjuncts to PTCA. These include
the use of the excimer laser for photoablation of plaque, rotational
atherectomy (use of a high-speed diamond-encrusted drill) for
mechanical ablation of plaque, and directional atherectomy for cutting
and removal of plaque.
How does coronary
artery disease develop?
Arteries that supply blood and oxygen to the heart muscles are called
coronary arteries. Coronary artery disease (CAD) occurs when
cholesterol plaque (a hard, thick substance comprised of varying
amounts of cholesterol, calcium, muscle cells, and connective tissue,
which accumulates locally in the artery walls) builds up in the walls
of these arteries, a process called arteriosclerosis. Over time,
arteriosclerosis causes significant narrowing of one or more coronary
arteries. When coronary arteries narrow more than 50 to 70%, the blood
supply beyond the plaque becomes inadequate to meet the increased
oxygen demand during exercise. Lack of oxygen (ischemia) in the heart
muscle causes chest pain (angina) in most patients. However, some 25%
of patients experience no chest pain at all despite documented
ischemia, or may only develop episodic shortness of breath instead of
chest pain. These patients have silent angina and have the same risk
of heart attack as those with angina. When arteries are narrowed in
excess of 90-99%, patients often have angina at rest (unstable
angina). When a blood clot (thrombus) forms on the plaque, the artery
may become completely blocked, causing death of a part of the heart
muscles (heart attack, or myocardial infarction).
The arteriosclerotic
process can be accelerated by smoking, high blood pressure, elevated
cholesterol and diabetes. Patients are also at higher risk for
arteriosclerosis if they are older (greater than 45 years for men and
55 years for women) or if they have a positive family history of
coronary heart disease.
How is coronary
artery disease diagnosed?
The resting electrocardiogram (EKG) is a recording of the electrical
activity of the heart, and can show changes indicative of ischemia or
heart attack. Often, the EKG in patients with coronary artery disease
is normal at rest, and only becomes abnormal when heart muscle
ischemia is brought on by exertion. Therefore, exercise treadmill or
bicycle testing (stress tests) are useful screening tests for patients
with significant coronary artery disease (CAD) and a normal resting
EKG. These stress tests are 60 to 70% accurate in diagnosing
significant CAD.
If the stress tests
are not diagnostic, a nuclear agent (cardiolyte or thallium) can be
given intravenously during stress tests. Addition of one of these
agents allows imaging of the blood flow to different regions of the
heart, using an external camera. An area of the heart with reduced
blood flow during exercise, but normal blood flow at rest, signifies
substantial artery narrowing in that region.
Stress
echocardiography combines echocardiography (ultrasound imaging of the
heart muscle) with exercise stress testing. It is also an accurate
technique for detecting CAD. When a significant narrowing exists, the
heart muscle supplied by the narrowed artery does not contract as well
as the rest of the heart muscle. Stress echocardiography and thallium
stress tests are 80% to 85% accurate in detecting significant CAD.
When a patient cannot
undergo an exercise stress test because of neurological or arthritic
difficulties, medications can be injected intravenously to simulate
the stress on the heart normally brought on by exercise. Heart imaging
can be performed with either a nuclear camera or echocardiography.
Cardiac
catheterization with angiography (coronary arteriography) is a
technique that allows x-ray pictures to be taken of the coronary
arteries. It is the most accurate test to detect coronary artery
narrowing. Small hollow plastic tubes (catheters) are advanced under
x-ray guidance to the openings of coronary arteries. Iodine contrast
"dye," is then injected into the arteries while an x-ray
video is recorded. Coronary arteriography gives the doctor a picture
of the location and severity of narrowed artery segments. This
information is important in helping the doctor select medications,
PTCA, or coronary artery bypass graft surgery (CABG) as the preferred
treatment option.
How is CAD treated?
Angina medications reduce the heart muscle's demand for oxygen in
order to compensate for the reduced blood supply, and also may
partially dilate the coronary arteries to enhance blood flow. Three
commonly used classes of drugs are the nitrates, beta blockers, and
calcium blockers. Examples of nitrates include Isosorbide (Isordil),
Isosorbide mononitrate (Imdur), and transdermal nitrate patches.
Examples of beta blockers include propranolol (Inderal), atenolol (Tenormin),
and metoprolol (Lopressor). Examples of calcium blockers include
Procardia, Verapamil, Diltiazem, and Norvasc. Many patients benefit
from these angina medications with reduction of angina during
exertion. When significant ischemia still occurs with exercise
testing, coronary arteriography is usually performed, often followed
by either PTCA or CABG.
Patients with unstable
angina have severe coronary artery narrowing and are at imminent risk
of heart attack. In addition to angina medications, they are given
aspirin and the intravenous blood thinner, heparin. A new form of
heparin, Lovenox , may be administered subcutaneously, and has been
demonstrated to be as effective as intravenous heparin in patients
with unstable angina. Aspirin prevents clumping of blood clotting
elements called platelets, while heparin prevents blood from clotting
on the surface of plaques. While patients with unstable angina may
have their symptoms temporarily controlled with these potent
medications, they are often at risk for the development of heart
attacks. For this reason, many patients with unstable angina are
referred for coronary angiography, and possible PTCA or CABG.
PTCA can produce
excellent results in carefully selected patients who may have one or
more severely narrowed artery segments which are suitable for balloon
dilatation, stenting, or atherectomy. During PTCA, a local anesthetic
is injected into the skin over the artery in the groin or arm. The
artery is punctured with a needle and a plastic sheath is placed into
the artery. Under x-ray guidance (fluoroscopy), a long, thin plastic
tube, called a guiding catheter, is advanced through the sheath to the
origin of the coronary artery from the aorta. A contrast dye
containing iodine is injected through the guiding catheter so that
x-ray images of the coronary arteries can be obtained. A small
diameter guide wire (0.014 inches) is threaded through the coronary
artery narrowing or blockage. A balloon catheter is then advanced over
the guide wire to the site of the obstruction. This balloon is then
inflated for about 1 minute, compressing the plaque and enlarging the
opening of the coronary artery. Balloon inflation pressures may vary
from as little as one or two atmospheres of pressure, to as much as 20
atmospheres. Finally, the balloon is deflated and removed from the
body.
Intracoronary stents
are deployed in either a self-expanding fashion, or most commonly they
are delivered over a conventional angioplasty balloon. When the
balloon is inflated, the stent is expanded and deployed, and the
balloon is removed - the stent remains in place in the artery.
Atherectomy devices are inserted into the coronary artery over a
standard angioplasty guide wire, and then activated in varying
fashion, depending on the device chosen.
CABG surgery is
performed to relieve angina in patients whose illness has not
responded to medications and are not good candidates for balloon
angioplasty. CABG is best performed in patients with multiple
blockages in multiple locations, or when blockages are located in
certain arterial segments which are not well-suited for PTCA. CABG is
often also used in patients who have failed to attain long-term
success following one or more PTCA procedures. CABG surgery has been
shown to improve long- term survival in patients with significant
narrowing of the left main coronary artery, and in patients with
significant narrowing in multiple arteries, especially in those with
decreased heart muscle pump function.
What are the
complications of PTCA?
PTCA, using balloons, stents, and/or atherectomy can achieve effective
relief of coronary arterial obstruction in 90% to 95% of the patients.
In a very small percentage of patients, PTCA cannot be performed
because of technical difficulties. These difficulties usually involve
the inability to pass the guide wire or the balloon catheter across
the narrowed artery segments. The most serious complication of PTCA
results when there is an abrupt closure of the dilated coronary artery
within the first few hours after the procedure. Abrupt coronary artery
closure occurs in 5% of patients after simple balloon angioplasty, and
is responsible for most of the serious complications related to PTCA.
Abrupt closure is due to a combination of tearing (dissection) of the
inner lining of the artery, blood clotting (thrombosis) at the balloon
site, and constriction (spasm) or elastic recoil of the artery at the
balloon site. To help prevent the process of thrombosis during or
after PTCA, aspirin is given to prevent platelets from adhering to the
artery wall and stimulating the formation of blood clots. Intravenous
heparin is given to further prevent blood clotting; and combinations
of nitrates and calcium blockers are used to minimize vessel spasm.
Individuals at an increased risk for abrupt closure include women,
patients with unstable angina, and patients having heart attacks. The
incidence of abrupt occlusion after PTCA has declined dramatically
with the introduction of coronary stents, which essentially eliminate
the problem of flow-limiting arterial dissections, elastic recoil, and
spasm. The use of new intravenous "super aspirins", which
alter platelet function at a site different from the site of
aspirin-inhibition, have dramatically reduced the incidence of
thrombosis after balloon angioplasty and stenting. Examples of these
newer agents include abciximab (Reopro), eptifibitide (Integrelin),
and tirofiban (Aggrastat); these agents represent a major advance in
enhancing the safety and efficacy of PTCA.
When despite these
measures, a coronary artery cannot be "kept open" during
PTCA, emergency CABG surgery may be necessary. Before the advent of
stents and advanced anti-thrombotic strategies, emergency CABG
following a failed PTCA was required in as many as 5% of patients. In
the current era, the need for emergent CABG following PTCA is less
than 1-2%.The overall acute mortality risk following PTCA is less than
one percent; the risk of a heart attack following PTCA is only about
1-2%. The degree of risk is dependent on the number of diseased
vessels treated, the function of the heart muscle, and the age and
clinical condition of the patient.
How do patients
recover after PTCA?
PTCA is performed in a special room fitted with computerized x-ray
equipment called a cardiac catheterization laboratory. Patients are
mildly sedated with small amounts of diazepam (Valium), midazolam
(Versed), morphine, and other sedative narcotics given intravenously.
Patients may experience minor discomfort at the site of the puncture
in the groin or the arm. Patients also may experience brief episodes
of angina while the balloon is inflated, briefly blocking the flow of
blood in the coronary artery. The PTCA procedure can last from 30
minutes to 2 hours, but is usually completed within 60 minutes.
Patients are then
brought to a monitored bed for observation. The plastic catheters left
in the artery are removed from the groin after 4 to 12 hours depending
on how long blood thinning is needed to stabilize the opened artery.
When these catheters are removed, the area is compressed by hand or
with the aid of a mechanical clamp for about 20 minutes to prevent
bleeding. In some instances, the artery in the groin may be sutured or
"sealed" in the catheterization laboratory, and the
catheters are immediately removed. This enables the patient to sit up
in bed within a few hours after the procedure. Most patients are
discharged home the day after PTCA. Patients are advised not to lift
anything heavier than 20 pounds or perform vigorous exertion for the
first 1 to 2 weeks after PTCA. This allows the area in the coronary
artery as well as the groin or arm arteries to heal. Patients may
return to normal work and sexual activity 2 or 3 days after PTCA.
Patients are maintained on aspirin indefinitely after PTCA to prevent
future thrombotic events (i.e., unstable angina or heart attack). In
patients who receive stents, an additional anti-platelet agent (eg:
ticlopidine, Ticlid or clopidrogel, Plavix) is given in conjunction
with aspirin for 2-4 weeks; this is because the metal in the stents
may promote the formation of blood clots in the first couple of weeks
after the stent is inserted. After 2 weeks, the metal of the stent is
coated with a natural tissue lining which no longer stimulates
platelets to form blood clots.
Exercise stress
testing is sometimes done several weeks after PTCA and signals the
beginning of a cardiac rehabilitation program. Rehabilitation can
involve a 12 week program of gradually increasing monitored exercise
lasting one hour 3 times a week. Lifestyle changes can help to lower
the patient's chance of developing further coronary artery disease.
These include stopping smoking, reducing weight and dietary fat,
controlling blood pressure and diabetes, and lowering blood
cholesterol levels. Cholesterol reduction is often aided by the
addition of medications which may not only lower cholesterol levels,
but may offer protection against future heart attacks.
What are the
long-term results of PTCA?
Long-term benefits of PTCA depend on the maintenance of the
newly-opened coronary artery(ies). 30-40% of patients with successful
PTCA will develop recurrent narrowing (restenosis) at the site of the
balloon inflation, usually within 6 months following PTCA. Patients
may complain of recurrence of angina or may have no symptoms.
Restenosis is often detected by exercise stress tests performed at 4
to 6 months after PTCA. Restenosis occurs with a significantly higher
frequency in patients with diabetes. The rate of restenosis is greater
in vein grafts, at the origins of vessels, in the beginning part of
the left anterior descending coronary artery, and in those with
suboptimal initial results. The widespread use of intracoronary stents
has reduced the incidence of restenosis by as much as 50% or more;
this is due to prevention of "elastic recoil" in the artery,
as well as providing a larger initial channel in the treated artery.
Restenosis can simply be observed or treated with medications if the
narrowing is not critical and the patient is not symptomatic. About
25% of patients undergo a repeat PTCA to increase coronary artery
blood flow. Second PTCA procedures have similar initial and long-term
results as first procedures. Sometimes, CABG surgeries are recommended
for those patients who have developed more extensive disease in the
restenosed artery as well as in the other coronary arteries. Patients
may also choose CABG surgery to avoid the uncertainty of restenosis
after the second PTCA. In patients with restenosis after balloon
angioplasty or stents, the use of atherectomy devices or intracoronary
radiation (brachytherapy) may reduce the risk of future restenosis. If
no evidence of restenosis is observed after 6-9 months, studies have
demonstrated that the treated arterial segment is likely to remain
open for many years. "Late restenosis" after one year or
more is very uncommon. Symptoms developing more than one year after
successful PTCA are usually due to blockage in a different segment of
the artery, or in a different artery from that which was treated in
the initial PTCA.
Source:
American Heart Association
Subscribe
If you would like to be added to the
distribution list to receive our newsletter via e-mail send
an e-mail to newsletter@AxiomLLC.com and type 'SUBSCRIBE' in the subject line.
Disclaimer
This information is being provided by Axiom Medical Consulting, LLC as a service. Users of
this information should make appropriate analysis and check the information to their own
satisfaction. Axiom does not warrant or represent, expressly or implied, the correctness
or accuracy of the content of the information presented in this e-mail, nor can they
accept liability or responsibility whatsoever for the consequences of its use or misuse by
anyone.
|